
WHAT IS CLAIMED IS:

1. Use of a combination of compounds for treating a disease or condition, wherein the combination includes an effective amount of Compound (A), or a pharmaceutically acceptable salt thereof, and an effective amount of one or more of Compound (B), or a pharmaceutically acceptable salt thereof,

wherein the Compound (A) has the structure:




(A)


wherein:


R^1 is selected from the group consisting of hydrogen, halogen and a substituted or unsubstituted C_1-C_6 alkyl;

Ring A is selected from the group consisting of a substituted or unsubstituted phenyl and a substituted or unsubstituted 5-6 membered monocyclic heteroaryl;

Ring B is selected from the group consisting of a substituted or unsubstituted monocyclic 5-7 membered carbocyclyl and a substituted or unsubstituted 5-7 membered monocyclic heterocyclyl;

R^2 is selected from the group consisting of 

, 

and 

;

m is 0, 1, 2 or 3;

R^3 is selected from the group consisting of halogen and a substituted or unsubstituted C_1-C_6 alkyl;

X is selected from the group consisting of hydrogen, halogen, hydroxy, cyano, a substituted or unsubstituted 4-6 membered monocyclic heterocyclyl, a substituted or unsubstituted amine(C_1-C_6 alkyl), a substituted or unsubstituted –NH-$(CH_2)_{1-6}$-amine, a mono-substituted amine, a di-substituted amine, an amino, a substituted or unsubstituted C_1-C_6 alkyl, a substituted or unsubstituted C_1-C_6 alkoxy, a substituted or unsubstituted C_3-C_6 cycloalkoxy, a substituted or

unsubstituted (C_1-C_6 alkyl)acyl, a substituted or unsubstituted C-amido, a substituted or unsubstituted N-amido, a substituted or unsubstituted C-carboxy, a substituted or unsubstituted O-carboxy, a substituted or unsubstituted O-carbamyl and a substituted or unsubstituted N-carbamyl;

Y is CH or N;

Y^1 is CR^{4A} or N;

Y^2 is CR^{4B} or N;

Ring C is selected from the group consisting of a substituted or unsubstituted monocyclic 5-7 membered carbocyclyl, a substituted or unsubstituted 5-7 membered monocyclic heterocyclyl and a substituted or unsubstituted 7-10 membered bicyclic heterocyclyl;

R^{4A} and R^{4B} are independently selected from the group consisting of hydrogen, halogen and an unsubstituted C_{1-4} alkyl; and

R^5 is a substituted or unsubstituted 5-7 membered monocyclic heterocyclyl; and

the one or more of Compound (B) is selected from the group consisting of a PARP inhibitor, a PD1 inhibitor, a PD-L1 inhibitor and a chemotherapeutic agent, or a pharmaceutically acceptable salt of any of the foregoing;



wherein the PARP inhibitor is selected from the group consisting of olaparib, niraparib, rucaparib, talazoparib, veliparib, pamiparib (BGB-290), iniparib (BSI 201), E7016 (Esai) and CEP-9722, and pharmaceutically acceptable salts of any of the foregoing;



wherein the PD1 inhibitor is selected from the group consisting of nivolumab, pembrolizumab, cemiplimab, spartalizumab, ABBV-181, lodapolimab, zimberelimab, toripalimab (Tuoyi), tislelizumab, camrelizumab, sintilimab (Tyvyt), GB226, AK105, HLX-10, AK103, BAT-1306, GSL-010, CS1003, LZM009 and SCT-I10A, and pharmaceutically acceptable salts of any of the foregoing;



wherein the PD-L1 inhibitor is selected from the group consisting of atezolizumab, avelumab, durvalumab, KN035, CS1001, SHR-1316, TQB2450, BGB-A333, KL-A167, KN046, MSB2311 and HLX-20, and pharmaceutically acceptable salts of any of the foregoing; and



wherein the chemotherapeutic agent is selected from the group consisting of carboplatin, cisplatin, paclitaxel, docetaxel, pegylated liposomal doxorubicin, doxorubicin, gemcitabine, cytarabine, fludarabine, fluorouracil (5-FU), irinotecan, topotecan, temozolomide, triapine, 5-azacytidine, capecitabine, AraC-FdUMP[10] (CF-10), cladribine, decitabine, hydroxyurea and oxaliplatin, and pharmaceutically acceptable salts of any of the foregoing.


2. The use of Claim 1, wherein the Compound (A) is selected from the group consisting of:

, ,



















, ,





















, ,

,  and

, or a pharmaceutically acceptable salt of any of the foregoing.

3. The use of Claim 1, wherein the Compound (A) is selected from the group consisting of:

















,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,



,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,



,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,


,




,


and


, or a pharmaceutically acceptable salt of any of the foregoing.

4. The use of Claim 1, wherein the Compound (A) is


, or a pharmaceutically acceptable salt thereof.

5. The use of Claim 1, wherein the Compound (A) is


, or a pharmaceutically acceptable salt thereof.

6. The use of any one of Claims 1-5, wherein the disease or condition is selected from the group consisting of a brain cancer, a cervicocerebral cancer, an esophageal cancer, a thyroid cancer, a lung cancer, a breast cancer, a stomach cancer, a gallbladder/bile duct cancer, a liver cancer, a pancreatic cancer, a gastric cancer, a colon cancer, a rectal cancer, an ovarian cancer, an endometrial cancer, a choriocarcinoma, an uterus body cancer, an uterocervical cancer, a renal pelvis/ureter cancer, a bladder cancer, a prostate cancer, a penis cancer, a testicular cancer, a fetal cancer, an uterine cancer, Wilms' cancer, a skin cancer, malignant melanoma, a neuroblastoma, an osteosarcoma, an Ewing's tumor, a soft part sarcoma, a head and neck squamous cell carcinoma, a glioblastoma, an acute leukemia, a chronic lymphatic leukemia, a chronic myelocytic leukemia,

polycythemia vera, a malignant lymphoma, multiple myeloma, a Hodgkin's lymphoma and a non-Hodgkin’s lymphoma.

7. The use of Claim 6, wherein the disease or condition is a lung cancer.

8. The use of Claim 7, wherein the lung cancer is small cell lung cancer (SCLC).

9. The use of Claim 7, wherein the lung cancer is non-small cell lung cancer (NSCLC).

10. The use of Claim 6, wherein the disease or condition is a breast cancer.

11. The use of Claim 10, wherein the breast cancer is triple negative breast cancer.

12. The use of Claim 6, wherein the disease or condition is a colon cancer.

13. The use of Claim 6, wherein the disease or condition is an ovarian cancer.

14. The use of Claim 13, wherein the ovarian cancer is TP53-mutated ovarian cancer.

15. The use of Claim 6, wherein the disease or condition is an uterine cancer.

16. The use of Claim 6, wherein the disease or condition is an endometrial cancer.

17. The use of Claim 16, wherein the endometrial cancer is uterine serous carcinoma.

18. The use of Claim 6, wherein the disease or condition is an osteosarcoma.

19. The use of any one of Claims 1-18, wherein the one or more of Compound (B), or a pharmaceutically acceptable salt thereof, is a PARP inhibitor, or a pharmaceutically acceptable salt thereof.

20. The use of Claim 19, wherein the PARP inhibitor, or a pharmaceutically acceptable salt thereof, is niraparib, talazoparib, and pharmaceutically acceptable salts of any of the foregoing.

21. The use of any one of Claims 1-18, wherein Compound (B), or a pharmaceutically acceptable salt thereof, is a chemotherapeutic agent, or a pharmaceutically acceptable salt thereof.

22. The use of Claim 21, wherein the chemotherapeutic agent is selected from the group consisting of carboplatin, doxorubicin, gemcitabine, triapine, hydroxyurea, and pharmaceutically acceptable salts of any of the foregoing.

23. The use of Claim 1, wherein the combination is being used for a subject that has been determined to have homologous recombination deficiency (HRD) positive status.

24. The use of Claim 1, wherein the combination is being used for a subject that has been determined to have homologous recombination deficiency (HRD) negative status.

25. The use of Claim 23 or 24, wherein the one or more of Compound (B), or a pharmaceutically acceptable salt thereof, is a PARP inhibitor, or a pharmaceutically acceptable salt thereof.

26. The use of Claim 25, wherein the PARP inhibitor, or a pharmaceutically acceptable salt thereof, is niraparib, or a pharmaceutically acceptable salt thereof.

27. The use of any one of Claims 23-24, wherein the disease or condition is selected from the group consisting of an ovarian cancer, a breast cancer, a prostate cancer, a fallopian tube cancer and a primary peritoneal cancer.

28. The use of Claim 27, wherein the ovarian cancer is recurrent ovarian cancer.

29. The use of Claim 27, wherein the breast cancer is selected from the group consisting of triple-negative breast cancer and metastatic breast cancer.

30. The use of Claim 27, wherein the prostate cancer is metastatic castration-resistant prostate cancer.